Comparative efficacy of three regimens (cyclosporine, tacrolimus, and cyclophosphamide) combined with steroids for the treatment of idiopathic membranous nephropathy.
Saved in:
| Title: | Comparative efficacy of three regimens (cyclosporine, tacrolimus, and cyclophosphamide) combined with steroids for the treatment of idiopathic membranous nephropathy. |
|---|---|
| Alternate Title: | E?ficacia comparativa de 3 regímenes (ciclosporina, tacrolimús y ciclofosfamida) combinados con esteroides para el tratamiento de la nefropatía membranosa idiopática. |
| Authors: | Chen Ruo-ji1, Xing Fang2, Du Zhen-shuang2, Zhang Yu-lin3, Zheng Zi-li1, Lin Wei-yuan2 linweiyuanmed@163.com |
| Source: | Nefrologia. Nov/Dec2022, Vol. 42 Issue 6, p671-679. 9p. |
| Subjects: | CYCLOSPORINE, TACROLIMUS, CYCLOPHOSPHAMIDE, KIDNEY diseases, RESPIRATORY infections |
| Abstract (English): | Introduction and objectives: To investigate the efficacy of combined immunosuppressive regimens of cyclosporine (CsA), tacrolimus (TAC), or cyclophosphamide (CTX) combined with steroids in the treatment of idiopathic membranous nephropathy (IMN). Materials and methods: A total of 150 biopsy-proven IMN patients were divided into three groups: CTX, TAC, and CsA groups (50 cases each). Patients received a selected regimen for 48 weeks. The efficacy (remission rate, 24 h urinary protein, and serum albumin and creatinine) and safety (adverse events) profiles of administered regimens were evaluated at 12, 24 and 48 weeks. Results: At 12 weeks, the response rates for CsA, TAC, and CTX groups were 14%, 50%, and 22%, respectively. This increased to 74%, 84%, and 82%, respectively at 48 weeks. During follow-up, 24 h urinary protein significantly reduced from baseline in all regimens (P < 0.05), while serum albumin increased in TAC and CTX groups after 12 weeks (P < 0.05), and CsA group at 48 weeks (P < 0.05). No significant changes in serum creatinine levels were noted in all three regimens (P > 0.05). Safety was comparable in all groups, with lower respiratory tract infection being the most frequent adverse event. Conclusions: The combined regimens (i.e., TAC, CsA, and CTX) are effective in the treatment of patients with IMN at 48 weeks, while TAC and CTX might be more beneficial in terms of shortened time to remission and increased complete response rate. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Introducción y objetivos: Investigar la eficacia de los regímenes inmunosupresores combinados de ciclosporina (CsA), tacrolimús (TAC) o ciclofosfamida (CTX) combinados con esteroides en el tratamiento de la nefropatía membranosa idiopática (NMI). Materiales y métodos: Un total de 150 pacientes con NMI comprobada por biopsia se dividieron en 3 grupos: grupos CTX, TAC y CsA (50 casos cada uno). Los pacientes recibieron un régimen seleccionado durante 48 semanas. Se evaluaron los perfiles de eficacia (tasa de remisión, proteína en orina de 24 h y albúmina y creatinina séricas) y seguridad (eventos adversos) de los regímenes administrados a las 12, 24 y 48 semanas. Resultados: A las 12 semanas, las tasas de respuesta para los grupos CsA, TAC y CTX fueron del 14, el 50 y el 22%, respectivamente. Esto aumentó al 74, el 84 y el 82%, respectivamente, a las 48 semanas. Durante el seguimiento, la proteína urinaria de 24 h se redujo significativamente desde el inicio en todos los regímenes (p < 0,05), mientras que la albúmina sérica aumentó en los grupos TAC y CTX después de 12 semanas (p < 0,05) y el grupo CsA a las 48 semanas (p < 0,05). No se observaron cambios significativos en los niveles de creatinina sérica en los 3 regímenes (p > 0.05). La seguridad fue comparable en todos los grupos, siendo la infección del tracto respiratorio inferior el evento adverso más frecuente. Conclusiones: Los regímenes combinados (es decir, TAC, CsA y CTX) son eficaces en el tratamiento de pacientes con NMI a las 48 semanas, mientras que TAC y CTX podrían ser más beneficiosos en términos de reducción del tiempo de remisión y aumento de la tasa de respuesta completa. [ABSTRACT FROM AUTHOR] |
| Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 162863535 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Comparative efficacy of three regimens (cyclosporine, tacrolimus, and cyclophosphamide) combined with steroids for the treatment of idiopathic membranous nephropathy. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: E?ficacia comparativa de 3 regímenes (ciclosporina, tacrolimús y ciclofosfamida) combinados con esteroides para el tratamiento de la nefropatía membranosa idiopática. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Chen+Ruo-ji%22">Chen Ruo-ji</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Xing+Fang%22">Xing Fang</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Du+Zhen-shuang%22">Du Zhen-shuang</searchLink><relatesTo>2</relatesTo><br /><searchLink fieldCode="AR" term="%22Zhang+Yu-lin%22">Zhang Yu-lin</searchLink><relatesTo>3</relatesTo><br /><searchLink fieldCode="AR" term="%22Zheng+Zi-li%22">Zheng Zi-li</searchLink><relatesTo>1</relatesTo><br /><searchLink fieldCode="AR" term="%22Lin+Wei-yuan%22">Lin Wei-yuan</searchLink><relatesTo>2</relatesTo><i> linweiyuanmed@163.com</i> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Nefrologia%22">Nefrologia</searchLink>. Nov/Dec2022, Vol. 42 Issue 6, p671-679. 9p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22CYCLOSPORINE%22">CYCLOSPORINE</searchLink><br /><searchLink fieldCode="DE" term="%22TACROLIMUS%22">TACROLIMUS</searchLink><br /><searchLink fieldCode="DE" term="%22CYCLOPHOSPHAMIDE%22">CYCLOPHOSPHAMIDE</searchLink><br /><searchLink fieldCode="DE" term="%22KIDNEY+diseases%22">KIDNEY diseases</searchLink><br /><searchLink fieldCode="DE" term="%22RESPIRATORY+infections%22">RESPIRATORY infections</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Introduction and objectives: To investigate the efficacy of combined immunosuppressive regimens of cyclosporine (CsA), tacrolimus (TAC), or cyclophosphamide (CTX) combined with steroids in the treatment of idiopathic membranous nephropathy (IMN). Materials and methods: A total of 150 biopsy-proven IMN patients were divided into three groups: CTX, TAC, and CsA groups (50 cases each). Patients received a selected regimen for 48 weeks. The efficacy (remission rate, 24 h urinary protein, and serum albumin and creatinine) and safety (adverse events) profiles of administered regimens were evaluated at 12, 24 and 48 weeks. Results: At 12 weeks, the response rates for CsA, TAC, and CTX groups were 14%, 50%, and 22%, respectively. This increased to 74%, 84%, and 82%, respectively at 48 weeks. During follow-up, 24 h urinary protein significantly reduced from baseline in all regimens (P < 0.05), while serum albumin increased in TAC and CTX groups after 12 weeks (P < 0.05), and CsA group at 48 weeks (P < 0.05). No significant changes in serum creatinine levels were noted in all three regimens (P > 0.05). Safety was comparable in all groups, with lower respiratory tract infection being the most frequent adverse event. Conclusions: The combined regimens (i.e., TAC, CsA, and CTX) are effective in the treatment of patients with IMN at 48 weeks, while TAC and CTX might be more beneficial in terms of shortened time to remission and increased complete response rate. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Introducción y objetivos: Investigar la eficacia de los regímenes inmunosupresores combinados de ciclosporina (CsA), tacrolimús (TAC) o ciclofosfamida (CTX) combinados con esteroides en el tratamiento de la nefropatía membranosa idiopática (NMI). Materiales y métodos: Un total de 150 pacientes con NMI comprobada por biopsia se dividieron en 3 grupos: grupos CTX, TAC y CsA (50 casos cada uno). Los pacientes recibieron un régimen seleccionado durante 48 semanas. Se evaluaron los perfiles de eficacia (tasa de remisión, proteína en orina de 24 h y albúmina y creatinina séricas) y seguridad (eventos adversos) de los regímenes administrados a las 12, 24 y 48 semanas. Resultados: A las 12 semanas, las tasas de respuesta para los grupos CsA, TAC y CTX fueron del 14, el 50 y el 22%, respectivamente. Esto aumentó al 74, el 84 y el 82%, respectivamente, a las 48 semanas. Durante el seguimiento, la proteína urinaria de 24 h se redujo significativamente desde el inicio en todos los regímenes (p < 0,05), mientras que la albúmina sérica aumentó en los grupos TAC y CTX después de 12 semanas (p < 0,05) y el grupo CsA a las 48 semanas (p < 0,05). No se observaron cambios significativos en los niveles de creatinina sérica en los 3 regímenes (p > 0.05). La seguridad fue comparable en todos los grupos, siendo la infección del tracto respiratorio inferior el evento adverso más frecuente. Conclusiones: Los regímenes combinados (es decir, TAC, CsA y CTX) son eficaces en el tratamiento de pacientes con NMI a las 48 semanas, mientras que TAC y CTX podrían ser más beneficiosos en términos de reducción del tiempo de remisión y aumento de la tasa de respuesta completa. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Nefrologia is the property of Revista Nefrologia and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=162863535 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.nefroe.2022.11.008 Languages: – Code: eng Text: English PhysicalDescription: Pagination: PageCount: 9 StartPage: 671 Subjects: – SubjectFull: CYCLOSPORINE Type: general – SubjectFull: TACROLIMUS Type: general – SubjectFull: CYCLOPHOSPHAMIDE Type: general – SubjectFull: KIDNEY diseases Type: general – SubjectFull: RESPIRATORY infections Type: general Titles: – TitleFull: Comparative efficacy of three regimens (cyclosporine, tacrolimus, and cyclophosphamide) combined with steroids for the treatment of idiopathic membranous nephropathy. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Chen Ruo-ji – PersonEntity: Name: NameFull: Xing Fang – PersonEntity: Name: NameFull: Du Zhen-shuang – PersonEntity: Name: NameFull: Zhang Yu-lin – PersonEntity: Name: NameFull: Zheng Zi-li – PersonEntity: Name: NameFull: Lin Wei-yuan IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: Nov/Dec2022 Type: published Y: 2022 Identifiers: – Type: issn-print Value: 02116995 Numbering: – Type: volume Value: 42 – Type: issue Value: 6 Titles: – TitleFull: Nefrologia Type: main |
| ResultId | 1 |
